Common use of DEVELOPMENT OF SHARED PRODUCTS Clause in Contracts

DEVELOPMENT OF SHARED PRODUCTS. The parties will use Commercially Reasonable Efforts to conduct the Development of Shared Products in accordance with the Development Plan. The role of each party in the Development process will be determined by the Steering Committee as described in Section 3.7, with the parties intending that each party will provide advisory and supporting services with respect to any phase of the process in which such party is not actively or primarily involved. Unless otherwise agreed by the parties, each party shall supply fifty percent (50%) of the total Development effort for each Shared Product in the aggregate, as determined by the Steering Committee. The costs of conducting such Development shall be shared by the parties as set forth in Section 3.8. The Steering Committee will determine appropriate written standards for measuring each party's required efforts and accounting procedures to confirm and document each party's performance of its required efforts for any Shared Product before the parties commence Development thereof. No clinical trials involving any Shared Product shall be commenced by or on *=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. behalf of either party without the prior approval of the Steering Committee. Nothing contained in this Section 3.6 shall be deemed to preclude either party from terminating its participation in the collaborative Development of a Shared Product pursuant to Section 3.14. Any decision by a party not to participate in Development of a Shared Product pursuant to Section 3.2, 3.3 or 3.4 or to terminate participation in the Development of a Shared Product pursuant to Section 3.14, shall not be deemed a breach of this Agreement. The parties will conduct Pre-Clinical Development, Development, Manufacturing and Commercialization activities in a manner calculated to minimize aggregate Development Costs for such Shared Compound and Shared Product consistent with the Development Plan and the Development Budget for such Shared Compound and Shared Product.

DEVELOPMENT OF SHARED PRODUCTS. The parties will use Commercially Reasonable Efforts to conduct the Development of Shared Products in accordance with the Development Plan. The role of each party in the Development process will be determined by the Steering Committee as described in Section 3.74A.7, with the parties intending that each party will provide advisory and supporting services with respect to any phase of the process in which such party is not actively or primarily involved. Unless otherwise agreed by the parties, each party shall supply fifty percent (50%) of the total Development effort for each Shared Product in the aggregate, as determined by the Steering Committee. The costs of conducting such Development shall be shared by the parties Parties as set forth in Section 3.84A.8. The Steering Committee will determine appropriate written standards for measuring each party's required efforts and accounting procedures to confirm and document each party's performance of its required efforts for any Shared Product before the parties commence Development thereof. No clinical trials involving any Shared Product shall be commenced by or on *=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. behalf of either party without the prior approval of the Steering Committee. Nothing contained in this Section 3.6 4A.6 shall be deemed to preclude either party from terminating its participation in the collaborative Development of a Shared Product pursuant to Section 3.144A.14. Any decision by a party not to *=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 24 participate in Development of a Shared Product pursuant to Section 3.24A.2, 3.3 4A.3 or 3.4 4A.4 or to terminate participation in the Development of a Shared Product pursuant to Section 3.144A.14, shall not be deemed a breach of this Agreement. The parties will conduct Pre-Clinical Development, Development, Manufacturing and Commercialization activities in a manner calculated to minimize aggregate Development Costs for such Shared Compound and Shared Product consistent with the Development Plan and the Development Budget for such Shared Compound and Shared Product.

DEVELOPMENT OF SHARED PRODUCTS. The parties will use Commercially Reasonable Efforts to conduct the Development of Shared Products in accordance with the Development Plan. The role of each party in the Development process will be determined by the Steering Committee as described in Section 3.7, with the parties intending that each party will provide advisory and supporting services with respect to any phase of the process in which such party is not actively or primarily involved. Unless otherwise agreed by the parties, each party shall supply fifty percent (50%) of the total Development effort for each Shared Product in the aggregate, as determined by the Steering Committee. The costs of conducting such Development shall be shared by the parties as set forth in Section 3.8. The Steering Committee will determine appropriate written standards for measuring each party's required efforts and accounting procedures to confirm and document each party's performance of its required efforts for any Shared Product before the parties commence Development thereof. No clinical trials involving any Shared Product shall be commenced by or on *=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. behalf of either party without the prior approval of the Steering Committee. Nothing contained in this Section 3.6 shall be deemed to preclude either party from terminating its participation in the collaborative Development of a Shared Product pursuant to Section 3.14. Any decision by a party not to participate in Development of a Shared Product pursuant to Section 3.2, 3.3 or 3.4 or to terminate participation in the Development of a Shared Product pursuant to Section 3.14, shall not be deemed a breach of this Agreement. The parties will conduct Pre-Clinical Development, Development, Manufacturing and Commercialization activities in a manner calculated to minimize aggregate Development Costs for such Shared Compound and Shared Product consistent with the Development Plan and the Development Budget for such Shared Compound and Shared Product. * = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

DEVELOPMENT OF SHARED PRODUCTS. The parties will use Commercially Reasonable Efforts to conduct the Development of Shared Products in accordance with the Development Plan. The role of each party in the Development process will be determined by the Steering Committee as described in Section 3.74A.7, with the parties intending that each party will provide advisory and supporting services with respect to any phase of the process in which such party is not actively or primarily involved. Unless otherwise agreed by the parties, each party shall supply fifty percent (50%) of the total Development effort for each Shared Product in the aggregate, as determined by the Steering Committee. The costs of conducting such Development shall be shared by the parties Parties as set forth in Section 3.84A.8. The Steering Committee will determine appropriate written standards for measuring each party's required efforts and accounting procedures to confirm and document each party's performance of its required efforts for any Shared Product before the parties commence Development thereof. No clinical trials involving any Shared Product shall be commenced by or on *=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. behalf of either party without the prior approval of the Steering Committee. Nothing contained in this Section 3.6 4A.6 shall be deemed to preclude either party from terminating its participation in the collaborative Development of a Shared Product pursuant to Section 3.144A.14. Any decision by a party not to participate in Development of a Shared Product pursuant to Section 3.24A.2, 3.3 4A.3 or 3.4 4A.4 or to terminate participation in the Development of a Shared Product pursuant to Section 3.144A.14, shall not be deemed a breach of this Agreement. The parties will conduct Pre-Clinical Development, Development, Manufacturing and Commercialization activities in a manner calculated to minimize aggregate Development Costs for such Shared Compound and Shared Product consistent with the Development Plan and the Development Budget for such Shared Compound and Shared Product.